Protalix BioTherapeutics Inc
Research Protalix BioTherapeutics Inc (PLX) on Bullrun: valuation model: 20.1% undervalued, market cap USD 223.99M, P/E 12.2. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPLX
- ExchangeNYSE MKT
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Valuation signal20.1% undervalued
- Market capUSD 223.99M
- P/E12.2
- Financial periodQ2 2026
- RevenueUSD 19.90M
- Net incomeUSD 3.78M
- Free cash flow-USD 10.99M
- Gross margin61.0%
Valuation Snapshot
Bullrun's latest valuation model marks Protalix BioTherapeutics Inc as 20.1% undervalued; latest market cap is USD 223.99M; P/E is 12.2.
Peer valuation comparison
Latest P/E is 12.24x versus a Healthcare sector median of 24.6x (50.2% below).
Latest P/E is 12.24x versus a United States median of 23.85x (48.7% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 52.74M | -USD 6.60M | -USD 13.63M | 48.8% | -0.08 | USD 14.68M | USD 8.32M | USD 48.23M |
| FY2024 | USD 53.40M | USD 2.93M | USD 7.39M | 54.5% | 0.04 | USD 19.76M | USD 5.53M | USD 43.21M |
| FY2023 | USD 65.49M | USD 8.31M | -USD 2.47M | 64.9% | 0.09 | USD 23.63M | USD 26.28M | USD 33.57M |
| FY2022 | USD 47.64M | -USD 14.93M | -USD 25.63M | 58.9% | -0.31 | USD 17.11M | USD 33.47M | -USD 10.64M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 223.99M | 12.2 | n/a | n/a |
| 2025 | 2025-12-31 | USD 144.77M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 142.60M | 62.7 | n/a | n/a |
| 2023 | 2023-12-29 | USD 129.85M | 44.5 | n/a | n/a |
| 2022 | 2022-12-30 | USD 69.41M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 37.81M | n/a | n/a | n/a |
About Protalix BioTherapeutics Inc
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Protalix BioTherapeutics Inc overvalued or undervalued?
Bullrun's valuation model currently marks Protalix BioTherapeutics Inc as 20.1% undervalued.
What is Protalix BioTherapeutics Inc's market cap?
Protalix BioTherapeutics Inc's market capitalization is USD 223.99M.
What is Protalix BioTherapeutics Inc's P/E ratio?
Protalix BioTherapeutics Inc's price-to-earnings (P/E) ratio is 12.2.
What does Protalix BioTherapeutics Inc do?
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.